A theranostic antibody designed to specifically detect PSMA helps to further differentiate between circulating S‐EVs from prostate cancer patients, for both CD9 and CD63 captured S‐EVs (Figures 1c and 1d), providing enhanced potential to assess heterogeneity of S‐EVs for prostate cancer diagnosis. This evidence concerns the gene CD9 and prostate carcinoma.